Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Gastroenterol Hepatol ; 39(3): 512-518, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38073066

RESUMO

BACKGROUND AND AIM: Although diet is one of the potential environmental factors affecting ulcerative colitis (UC), evidence is not sufficient to draw definitive conclusions. This Japanese case-control study examined the association between the consumption of coffee, other caffeine-containing beverages and food, and total caffeine and the risk of UC. METHODS: The study involved 384 UC cases and 665 control subjects. Intake of coffee, decaffeinated coffee, black tea, green tea, oolong tea, carbonated soft drinks, and chocolate snacks was measured with a semiquantitative food-frequency questionnaire. Adjustments were made for sex, age, pack-years of smoking, alcohol consumption, history of appendicitis, family history of UC, education level, body mass index, and intake of vitamin C, retinol, and total energy. RESULTS: Higher consumption of coffee and carbonated soft drinks was associated with a reduced risk of UC with a significant dose-response relationship (P for trend for coffee and carbonated soft drinks were <0.0001 and 0.01, respectively), whereas higher consumption of chocolate snacks was significantly associated with an increased risk of UC. No association was observed between consumption of decaffeinated coffee, black tea, green tea, or oolong tea and the risk of UC. Total caffeine intake was inversely associated with the risk of UC; the adjusted odds ratio between extreme quartiles was 0.44 (95% confidence interval: 0.29-0.67; P for trend <0.0001). CONCLUSIONS: We confirmed that intake of coffee and caffeine is also associated with a reduced risk of UC in Japan where people consume relatively low quantities of coffee compared with Western countries.


Assuntos
Café , Colite Ulcerativa , Humanos , Cafeína/efeitos adversos , Cafeína/análise , Japão/epidemiologia , Estudos de Casos e Controles , Colite Ulcerativa/epidemiologia , Colite Ulcerativa/etiologia , Colite Ulcerativa/prevenção & controle , Fatores de Risco , Chá/efeitos adversos
2.
Digestion ; 104(1): 74-81, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36366823

RESUMO

BACKGROUND: The specific etiopathogenesis of inflammatory bowel disease (IBD) is still unknown. Although the conventional anti-inflammatory or immunomodulatory drugs relatively nonspecific to pathogenesis have been quite useful in many cases, elucidating the pathogenesis has gradually facilitated developments of disease-specific therapies for refractory cases in the last 2 decades. SUMMARY: With a greater understanding of the multiple overactive signaling pathways of the gut mucosal immune response and enhanced leukocyte trafficking, several biological agents or small molecule drugs following the first novel biologic, anti-tumor necrosis factor α (anti-TNFα), have been developed against several modes of action including adhesion molecules, sphingosine-1-phospate receptors, cytokines (IL-12/23, TL1A, and IL-36), Janus kinase (JAK), and phosphodiesterase. Although preceding biological agents have dramatically changed the IBD treatment strategy, many patients still require alternative therapies due to failure or side effects. Newer treatments are now expected to be provided for better efficacy with an improved adverse event profile. In addition, translational studies have highlighted the new therapeutic concepts' potential, including modulation of host-microbiome interactions, stem therapy for perianal fistula, regulation of fibrosis, regulation of the gut-brain axis, and control of previously less targeted immune cells (B cells and innate lymphoid cells). This paper comprehensively reviewed not only the latest already or shortly available therapies but also emerging promising treatments that will be hopefully established in the future for IBD. KEY MESSAGES: Many kinds of new treatments are available, and promising treatments with new perspectives are expected to emerge for refractory IBD in the future.


Assuntos
Imunidade Inata , Doenças Inflamatórias Intestinais , Humanos , Linfócitos/metabolismo , Doenças Inflamatórias Intestinais/tratamento farmacológico , Citocinas/metabolismo , Fator de Necrose Tumoral alfa
4.
World J Gastroenterol ; 21(1): 177-86, 2015 Jan 07.
Artigo em Inglês | MEDLINE | ID: mdl-25574090

RESUMO

AIM: To investigate the effect of a fat rich diet on non-steroidal anti-inflammatory drug (NSAID)-induced mucosal damage in the murine small intestine. METHODS: C57BL6 mice were fed 4 types of diets with or without indomethacin. One group was fed standard laboratory chow. The other groups were fed a fat diet consisting of 8% w/w fat, beef tallow (rich in SFA), fish oil, (rich in omega-3 PUFA), or safflower oil (rich in omega-6 PUFA). Indomethacin (3 mg/kg) was injected intraperitoneally from day 8 to day 10. On day 11, intestines and adhesions to submucosal microvessels were examined. RESULTS: In the indomethacin-treated groups, mucosal damage was exacerbated by diets containing beef tallow and fish oil, and was accompanied by leukocyte infiltration (P < 0.05). The mucosal damage induced by indomethacin was significantly lower in mice fed the safflower oil diet than in mice fed the beef tallow or fish oil diet (P < 0.05). Indomethacin increased monocyte and platelet migration to the intestinal mucosa, whereas safflower oil significantly decreased monocyte and platelet recruitment (P < 0.05). CONCLUSION: A diet rich in SFA and omega-3 PUFA exacerbated NSAID-induced small intestinal damage via increased leukocyte infiltration. Importantly, a diet rich in omega-6-PUFA did not aggravate inflammation as monocyte migration was blocked.


Assuntos
Anti-Inflamatórios não Esteroides/toxicidade , Dieta , Ácidos Graxos Ômega-6/administração & dosagem , Indometacina/toxicidade , Mucosa Intestinal/irrigação sanguínea , Mucosa Intestinal/efeitos dos fármacos , Intestino Delgado/irrigação sanguínea , Intestino Delgado/efeitos dos fármacos , Óleo de Cártamo/administração & dosagem , Animais , Plaquetas/efeitos dos fármacos , Plaquetas/imunologia , Plaquetas/metabolismo , Adesão Celular/efeitos dos fármacos , Moléculas de Adesão Celular/genética , Moléculas de Adesão Celular/metabolismo , Quimiotaxia de Leucócito/efeitos dos fármacos , Óleos de Peixe/administração & dosagem , Óleos de Peixe/toxicidade , Mucosa Intestinal/imunologia , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Intestino Delgado/imunologia , Intestino Delgado/metabolismo , Intestino Delgado/patologia , Leucócitos/efeitos dos fármacos , Leucócitos/imunologia , Leucócitos/metabolismo , Masculino , Produtos da Carne/toxicidade , Camundongos Endogâmicos C57BL , Microvasos/efeitos dos fármacos , Microvasos/imunologia , Microvasos/metabolismo , RNA Mensageiro/metabolismo , Fatores de Tempo
5.
Dig Endosc ; 26(4): 594-8, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23902595

RESUMO

Phlebosclerotic colitis is a rare and recently known disease entity and its etiology is still to be elucidated. Some phlebosclerotic colitis cases are difficult to distinguish from collagenous colitis because of the similarity of pathological findings. In all Japanese case reports of phlebosclerotic colitis in which an association with the use of Chinese herbal medicine is suspected, sansisi (gardenia fruit) was included, suggesting pathogenesis of this disease. We report a case of phlebosclerotic colitis that wasdifficult to be distinguished from collagenous colitis, and an association with the use of Chinese herbal medicine was suspected as the cause of the disease.


Assuntos
Colite Isquêmica/induzido quimicamente , Colite Isquêmica/diagnóstico , Medicamentos de Ervas Chinesas/efeitos adversos , Lansoprazol/efeitos adversos , Idoso , Angiografia , Biópsia , Colite Colagenosa/diagnóstico , Colonoscopia , Diagnóstico Diferencial , Humanos , Masculino , Tomografia Computadorizada por Raios X
6.
J Gastroenterol Hepatol ; 28 Suppl 4: 33-6, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24251701

RESUMO

Dietary fat has multiple roles on human health, and some dietary fat is used to treat organic diseases because of its anti-inflammatory effect. It is commonly accepted that omega-3 polyunsaturated fatty acid (PUFA) is beneficial on ischemic heart disease or rheumatic arthritis. On the contrary, effect of omega-3-PUFA on Crohn's disease remained controversial. That effect of omega-3 PUFA differs according to the location of inflamed intestine was hypothesized. To elucidate this hypothesis, to investigate the role of dietary fat on disease activity in different kind of murine models of intestinal inflammatory diseases was planned. The effect of omega-3 PUFA on small intestinal Crohn's disease model and large intestinal Crohn's disease model of mice. Chronic colitis model C57BL/6 mice received two cycles of dextran sodium sulfate solution treatment to induce chronic colitis. Feeding of omega-3 fat-rich diets exacerbated colitis with decrease in adiponectin expression. Chronic small intestinal inflammation model: SAMP1/Yit mice showed remarkable inflammation of the terminal ileum spontaneously. Feeding of omega-3 fat-rich diets for 16 weeks significantly ameliorated the inflammation of the terminal ileum. Enhanced infiltration of leukocytes and expression of mucosal addressin cell adhesion molecule-1 in intestinal mucosa was significantly decreased by omega-3 fat-rich diets treatment. Omega-3 PUFA has dual role, pro-/anti-inflammatory, on intestinal inflammatory diseases. The role of omega-3 fat and the potential for immunonutrition in inflammatory conditions of the gastrointestinal tract will be discussed.


Assuntos
Ácidos Graxos Ômega-3/efeitos adversos , Ácidos Graxos Ômega-3/uso terapêutico , Doenças Inflamatórias Intestinais/tratamento farmacológico , Adiponectina/metabolismo , Animais , Anti-Inflamatórios , Molécula 1 de Adesão Celular , Moléculas de Adesão Celular/metabolismo , Doença Crônica , Colite/induzido quimicamente , Modelos Animais de Doenças , Ácidos Graxos Ômega-3/farmacologia , Íleo , Imunoglobulinas/metabolismo , Mediadores da Inflamação , Mucosa Intestinal/imunologia , Mucosa Intestinal/metabolismo , Leucócitos/imunologia , Camundongos , Camundongos Endogâmicos C57BL , Isquemia Miocárdica/tratamento farmacológico , Febre Reumática/tratamento farmacológico
7.
Am J Physiol Gastrointest Liver Physiol ; 304(8): G708-14, 2013 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-23370677

RESUMO

Glucagon-like peptide-2 (GLP-2) is a potent intestinal growth factor derived from enteroendocrine L cells. Although food intake is known to increase GLP-2 secretion, its regulatory mechanisms are largely unknown as a result of its very short half-life in venules. The aims of this study were to compare the effects of luminal nutrients on the stimulation of GLP-2 secretion in vivo using lymph samples and to clarify the involvement of the sweet taste receptor in this process in vitro. Lymph samples were collected from the thoracic duct after bolus administration of dietary lipids or sweetening agents into the duodenum of rats. Human enteroendocrine NCI-H716 cells were also used to compare the effects of various nutrients on GLP-2 secretion. GLP-2 concentrations were measured by ELISA in vivo and in vitro. GLP-2 secretion was enhanced by polyunsaturated fatty acid- and monounsaturated fatty acid-rich dietary oils, dietary carbohydrates, and some kinds of sweeteners in rats; this effect was reproduced in NCI-H716 cells using α-linolenic acid (αLA), glucose, and sweeteners. GLP-2 secretion induced by sweetening agents was inhibited by lactisole, a sweetness-antagonizing inhibitor of T1R3. In contrast, lactisole was unable to inhibit GLP-2 secretion induced by αLA alone. Our results suggested that fatty acid- and sweetener-induced GLP-2 secretion may be mediated by two different pathways, with the sweet taste receptor involved in the regulation of the latter.


Assuntos
Gorduras na Dieta/farmacologia , Células Enteroendócrinas/metabolismo , Peptídeo 2 Semelhante ao Glucagon/metabolismo , Edulcorantes/farmacologia , Paladar/fisiologia , Animais , Derivados de Benzeno/farmacologia , Linhagem Celular Tumoral , Carboidratos da Dieta/farmacologia , Células Enteroendócrinas/citologia , Ácidos Graxos Monoinsaturados/farmacologia , Ácidos Graxos Insaturados/farmacologia , Glucose/farmacologia , Humanos , Sistema Linfático/metabolismo , Masculino , Ratos , Ratos Wistar , Ducto Torácico/metabolismo , Vênulas/metabolismo
8.
Microcirculation ; 17(5): 321-32, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20618690

RESUMO

OBJECTIVE: Aberrant leukocyte migration has been implicated in the pathogenesis of inflammatory bowel disease (IBD). Lemon grass is a natural herb that contains citral, which suppresses lymphocyte expression of gut homing molecules by inhibiting retinoic acid formation. We therefore hypothesized that lemon grass intake could ameliorate excess migration of leukocytes to the inflamed intestine in chronic ileitis. METHODS: Migration of fluorescence-labeled T cells to microvessels in the ileal mucosa of SAMP1/Yit mice was monitored using intravital microscopy. In some mice, lemon grass solution was administered for two weeks. For evaluation of the effects on chronic ileitis, mice were treated with lemon grass for 26 weeks. RESULTS: Surface expression of beta7 and CCR9 on T lymphocytes was stronger in SAMP1/Yit mice than in AKR/J mice. Lemon grass treatment attenuated the surface expression of beta7-integrin and CCR9. The number of adherent lymphocytes to microvessels in chronic inflamed ileum was significantly few when lymphocytes were isolated from lemon grass treated mice. Long-term lemon grass treatment improved ileitis in SAMP1/Yit mice, which was assessed by body weight, histological changes and the infiltration of beta7-positive cells. CONCLUSION: Lemon grass ameliorated ileitis through decreasing lymphocyte migration by inhibiting beta7-expression, suggesting its therapeutic usefulness for IBD.


Assuntos
Cymbopogon , Ileíte/tratamento farmacológico , Fitoterapia , Linfócitos T/efeitos dos fármacos , Oxirredutases do Álcool/genética , Oxirredutases do Álcool/metabolismo , Animais , Movimento Celular/efeitos dos fármacos , Ileíte/imunologia , Ileíte/patologia , Íleo/irrigação sanguínea , Íleo/efeitos dos fármacos , Íleo/patologia , Cadeias beta de Integrinas/metabolismo , Mucosa Intestinal/irrigação sanguínea , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/patologia , Camundongos , Camundongos Endogâmicos AKR , Microscopia de Fluorescência , Microvasos/efeitos dos fármacos , Microvasos/patologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Receptores CCR/metabolismo , Linfócitos T/patologia , Linfócitos T/fisiologia , Tretinoína/metabolismo
9.
World J Gastroenterol ; 16(2): 184-92, 2010 Jan 14.
Artigo em Inglês | MEDLINE | ID: mdl-20066737

RESUMO

AIM: To elucidate the effect of antioxidants, resveratrol (RVT) and astaxanthin (AXN), on hepatitis C virus (HCV) replication. METHODS: We investigated the effect of recent popular antioxidant supplements on replication of the HCV replicon system OR6. RVT is a strong antioxidant and a kind of polyphenol that inhibits replication of various viruses. AXN is also a strong antioxidant. The replication of HCV RNA was assessed by the luciferase reporter assay. An additive effect of antioxidants on antiviral effects of interferon (IFN) and ribavirin (RBV) was investigated. RESULTS: This is the first report to investigate the effect of RVT and AXN on HCV replication. In contrast to other reported viruses, RVT significantly enhanced HCV RNA replication. Vitamin E also enhanced HCV RNA replication as reported previously, although AXN did not affect replication. IFN and RBV significantly reduced HCV RNA replication, but these effects were dose-dependently hampered and attenuated by the addition of RVT. AXN did not affect antiviral effects of IFN or RBV. CONCLUSION: These results suggested that RVT is not suitable as an antioxidant therapy for chronic hepatitis C.


Assuntos
Antioxidantes/farmacologia , Hepacivirus/fisiologia , Estilbenos/farmacologia , Replicação Viral/efeitos dos fármacos , Antioxidantes/uso terapêutico , Antivirais/farmacologia , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Hepacivirus/efeitos dos fármacos , Hepacivirus/genética , Hepatite C Crônica/tratamento farmacológico , Humanos , Interferons/farmacologia , RNA Viral/metabolismo , Resveratrol , Ribavirina/farmacologia , Estilbenos/uso terapêutico , Xantofilas/farmacologia
10.
Inflamm Bowel Dis ; 14(10): 1348-57, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18484673

RESUMO

BACKGROUND: Although the immunoregulatory effects of omega-3 fatty acid and adiponectin have been postulated, their role in intestinal inflammation is controversial. The aim of this study was to determine whether dietary fat intake influences activity of colonic inflammation through modulating this system. METHODS: C57BL/6 mice received dextran sulfate sodium for induction of colitis. Mice were fed a control diet, omega-3 fat-rich diet, omega-6 fat-rich diet, or saturated fat-rich diet. Some mice were administered a peroxisome proliferator activated receptor-gamma; agonist, pioglitazone. Messenger RNA expression of adiponectin and its receptors were analyzed. Adiponectin expression in colonic mucosa of ulcerative colitis patients was also analyzed. RESULTS: The receptors for adiponectin were found to be ubiquitously expressed in epithelial cells, intraepithelial lymphocytes, lamina proprial mononuclear cells, and subepithelial myofibroblasts from colonic tissue, but adiponectin was only expressed in myofibroblasts. Induction of colitis significantly decreased the expression of adiponectin in colonic mucosa. The omega-3 fat diet group, but not the other fat diet groups, showed exacerbated colitis with a further decrease of adiponectin expression. Pioglitazone treatment ameliorated the level of decrease in adiponectin expression and improved colonic inflammation induced by the omega-3 fat-rich diet. In patients with ulcerative colitis, the expression level of adiponectin in colonic mucosa was also decreased compared with that in control mucosa. CONCLUSIONS: Adiponectin was found to be expressed in myofibroblasts. Adiponectin expression was significantly suppressed by induction of colitis, and aggravation of colitis after exposure to omega-3 fat may be due to a further decrease in the expression level of adiponectin.


Assuntos
Adiponectina/metabolismo , Colite/induzido quimicamente , Colite/tratamento farmacológico , Gorduras Insaturadas na Dieta/administração & dosagem , Ácidos Graxos Ômega-3/administração & dosagem , Mioblastos/metabolismo , Adiponectina/genética , Animais , Anti-Inflamatórios/administração & dosagem , Células Cultivadas , Colite/metabolismo , Colite/patologia , Sulfato de Dextrana/toxicidade , Gorduras na Dieta/administração & dosagem , Modelos Animais de Doenças , Ácidos Graxos Ômega-6/administração & dosagem , Expressão Gênica , Humanos , Mucosa Intestinal/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Pioglitazona , RNA Mensageiro/metabolismo , Distribuição Aleatória , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Tiazolidinedionas
11.
J Gastroenterol Hepatol ; 22(11): 1838-45, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17914958

RESUMO

BACKGROUND AND AIM: Dietary fat is known to modulate immune functions. Intake of an animal fat-rich diet has been linked to increased risk of inflammation; however, little is known about how animal fat ingestion directly affects intestinal immune function. The objective of this study was to assess the effect of butter feeding on lymphocyte migration in intestinal mucosa and the changes in adhesion molecules and cytokines involved in this effect. METHODS: T-lymphocytes isolated from the spleen were fluorescence-labeled and injected into recipient mice. Butter was administered into the duodenum, and villus microvessels of the small intestinal mucosa were observed under an intravital microscope. mRNA expression of adhesion molecules and cytokines in the intestinal mucosa were determined by quantitative PCR. The effect of butter feeding on tumor necrosis factor (TNF)-alpha mRNA expression of intestinal macrophages was also determined. RESULTS: Intraluminal butter administration significantly increased lymphocyte adherence to intestinal microvessels accompanied by increases in expression levels of adhesion molecules ICAM-1, MAdCAM-1 and VCAM-1. This accumulation was significantly attenuated by anti-MAdCAM-1 and anti-ICAM-1 antibodies. Butter administration significantly increased TNF-alpha in the lamina proprial macrophages but not interleukin-6. Anti-TNF-alpha treatment attenuated the enhanced expression of adhesion molecules induced by butter administration. CONCLUSION: T-lymphocyte adherence to microvessels of the small intestinal mucosa was significantly enhanced after butter ingestion. This enhancement is due to increase in expression levels of adhesion molecules of the intestinal mucosa, which is mediated by TNF-alpha from macrophages in the intestinal lamina propria.


Assuntos
Manteiga , Adesão Celular/efeitos dos fármacos , Quimiotaxia de Leucócito/efeitos dos fármacos , Gorduras na Dieta/farmacologia , Mucosa Intestinal/efeitos dos fármacos , Macrófagos/efeitos dos fármacos , Linfócitos T/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismo , Animais , Anticorpos , Moléculas de Adesão Celular/imunologia , Moléculas de Adesão Celular/metabolismo , Gorduras na Dieta/administração & dosagem , Feminino , Imuno-Histoquímica , Molécula 1 de Adesão Intercelular/imunologia , Molécula 1 de Adesão Intercelular/metabolismo , Interleucina-6/metabolismo , Mucosa Intestinal/irrigação sanguínea , Mucosa Intestinal/metabolismo , Intubação Gastrointestinal , Ácido Linoleico/farmacologia , Macrófagos/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Microcirculação/efeitos dos fármacos , Microscopia de Vídeo , Microvilosidades/efeitos dos fármacos , Microvilosidades/metabolismo , Mucoproteínas , Ácido Oleico/farmacologia , Azeite de Oliva , Óleos de Plantas/farmacologia , Reação em Cadeia da Polimerase , RNA Mensageiro/metabolismo , Linfócitos T/metabolismo , Fatores de Tempo , Fator de Necrose Tumoral alfa/genética , Regulação para Cima , Molécula 1 de Adesão de Célula Vascular/imunologia , Molécula 1 de Adesão de Célula Vascular/metabolismo
12.
Int J Cancer ; 117(3): 499-505, 2005 Nov 10.
Artigo em Inglês | MEDLINE | ID: mdl-15906361

RESUMO

Most cases of pancreatic cancer are inoperable when diagnosed. Since immunotherapy and antiangiogenic therapy have been reported to be promising for pancreatic cancer, we examined whether the combination of immunotherapy with dendritic cells (DCs) and the antiangiogenic drug TNP-470 induces tumor regression. Syngeneic mouse pancreatic adenocarcinoma cells were orthotopically inoculated into C57/BL6 mice. DCs with or without tumor lysate (TL) were administered i.p. at 4 and 5 weeks. TNP-470 was injected s.c. into tumor-bearing mice every other day from 4 weeks to 6 weeks. We compared anticancer effects in 6 groups: NT (no treatment), DC/TL- (DCs without TL), DC/TL+ (DCs pulsed with TL), TNP (TNP-470 alone), DC/TL-TNP (DC/TL- plus TNP-470) and DC/TL+TNP (DC/TL+ plus TNP-470). We measured tumor volume, mean vascular density (MVD) and vessel diameter by FITC-dextran using an intravital microscope; degrees of proliferation and apoptosis of cancer cells by PCNA and TUNEL; infiltrating lymphocytes and expression levels of VEGF and MMP-9 by immunohistochemistry and immunoblotting. Tumor volume and MVD were significantly suppressed in the treatment groups with prolonged survival rate, especially in the DC/TL+TNP group. There were no significant differences in apoptosis among the 6 groups except DC/TL+. The number of infiltrating CD4+ cells in the DC/TL+ group was higher than that in the NT group. VEGF expression was significantly suppressed in the treatment groups containing TNP-470, and MMP-9 was also suppressed in the groups containing DC/TL+. Our data suggested that TL-pulsed DCs combined with TNP-470 induced regression of mouse pancreatic cancer, possibly through induction of immune responses and suppression of angiogenesis.


Assuntos
Inibidores da Angiogênese/uso terapêutico , Antibióticos Antineoplásicos/uso terapêutico , Células Dendríticas/imunologia , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/imunologia , Sesquiterpenos/uso terapêutico , Adenocarcinoma/irrigação sanguínea , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/imunologia , Adenocarcinoma/patologia , Animais , Divisão Celular , Sobrevivência Celular , Terapia Combinada , Cicloexanos , Modelos Animais de Doenças , Imunoterapia , Ativação Linfocitária , Transfusão de Linfócitos , Camundongos , O-(Cloroacetilcarbamoil)fumagilol , Neoplasias Pancreáticas/irrigação sanguínea , Neoplasias Pancreáticas/patologia , Baço/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA